share_log

Senti Biosciences Announces FDA Clearance Of IND Application For SENTI-202 For The Treatment Of Relapsed Or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia

Benzinga ·  Dec 22, 2023 06:36
Senti Biosciences Announces FDA Clearance Of IND Application For SENTI-202 For The Treatment Of Relapsed Or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment